Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Combination With EGFR or PD-1 Inhibition in R/M HNSCC
NCT03646461Phase 2Terminated
- Sponsor
- University of California, San Diego
- Start
- Oct 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of California, San Diego. Started Oct 2018; status: terminated.
02
Drugs
ibrutinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03646461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646461.